Drug intelligence / Profile preview

lidocaine + epinephrine + sufentanil

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Intrathecal, Epidural
01

Overview

This is a combination of three drugs—lidocaine, epinephrine, and sufentanil—used primarily in regional (spinal or epidural) anesthesia for surgical procedures.\n- **Lidocaine** is an amide-type local anesthetic that blocks sodium channels on neuronal cell membranes, preventing nerve impulse conduction and resulting in loss of sensation at the site of administration. It is also classified as a class Ib antiarrhythmic agent[4][5].\n- **Epinephrine** (adrenaline) acts as a vasoconstrictor by stimulating alpha-adrenergic receptors, reducing local blood flow to prolong the effect of lidocaine and decrease systemic absorption. This helps maintain anesthesia at the target site and reduces bleeding[5].\n- **Sufentanil** is a potent synthetic opioid analgesic that acts primarily on mu-opioid receptors to provide profound analgesia. It is used as an adjunct to enhance pain control during anesthesia[1][6].\n\nThe combination aims to optimize surgical anesthesia by providing rapid onset (from lidocaine), prolonged duration (with epinephrine), and strong analgesia (from sufentanil). This regimen has been studied for use in spinal or epidural anesthesia for procedures such as cesarean section or lower limb surgery[2][3].

02

Targets

NaV (Voltage-gated sodium channels)ADRA1A (α1A)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on lidocaine + epinephrine + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + epinephrine + sufentanil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call